430 related articles for article (PubMed ID: 19683731)
1. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G
J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction.
Franco I; Horowitz M; Grady R; Adams RC; de Jong TP; Lindert K; Albrecht D
J Urol; 2005 Jan; 173(1):221-5. PubMed ID: 15592080
[TBL] [Abstract][Full Text] [Related]
4. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
[TBL] [Abstract][Full Text] [Related]
5. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ;
Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
[TBL] [Abstract][Full Text] [Related]
6. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
Madersbacher H; Mürtz G; Alloussi S; Domurath B; Henne T; Körner I; Niedeggen A; Nounla J; Pannek J; Schulte-Baukloh H; Schultz-Lampel D; Bock P; Strugala G
BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
[TBL] [Abstract][Full Text] [Related]
9. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
Davila GW; Daugherty CA; Sanders SW;
J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
[TBL] [Abstract][Full Text] [Related]
10. Transdermal oxybutynin for overactive bladder.
Davila GW; Starkman JS; Dmochowski RR
Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study.
Grigoleit U; Mürtz G; Laschke S; Schuldt M; Goepel M; Kramer G; Stöhrer M
Eur Urol; 2006 Jun; 49(6):1114-20; discussion 1120-1. PubMed ID: 16542772
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
[TBL] [Abstract][Full Text] [Related]
13. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
Staskin DR; Robinson D
Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278
[TBL] [Abstract][Full Text] [Related]
14. Detrusor overactivity in spina bifida: how long does it need to be treated?
Ab E; Dik P; Klijn AJ; van Gool JD; de Jong TP
Neurourol Urodyn; 2004; 23(7):685-8. PubMed ID: 15382196
[TBL] [Abstract][Full Text] [Related]
15. Prospective open label study of solifenacin for overactive bladder in children.
Bolduc S; Moore K; Nadeau G; Lebel S; Lamontagne P; Hamel M
J Urol; 2010 Oct; 184(4 Suppl):1668-73. PubMed ID: 20728124
[TBL] [Abstract][Full Text] [Related]
16. Transdermal oxybutynin: sticking to the facts.
Cartwright R; Cardozo L
Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity.
Reddy PP; Borgstein NG; Nijman RJ; Ellsworth PI
J Pediatr Urol; 2008 Dec; 4(6):428-33. PubMed ID: 19013412
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
[TBL] [Abstract][Full Text] [Related]
19. [Effects of long-term administration of oxybutynin hydrochloride (KL007) for the treatment of neurogenic bladder and unstable bladder].
Sonoda T; Sakurai T; Yamada K; Mizutani S; Tsujimoto Y; Ogawa T
Hinyokika Kiyo; 1989 Jan; 35(1):167-78. PubMed ID: 2658513
[TBL] [Abstract][Full Text] [Related]
20. Oxybutynin in detrusor overactivity.
Diokno A; Ingber M
Urol Clin North Am; 2006 Nov; 33(4):439-45, vii. PubMed ID: 17011379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]